There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Cancer Research UK & University College London Cancer Trials Centre, London, UK Background: The combination of cisplatin and etoposide (PE) has been a standard treatment for patients with ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Medically reviewed by Renita White, MD Cancer that develops in the ovaries (the egg-producing reproductive organs) is ...

Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible to receive Tecentriq plus carboplatin and etoposide. NICE noted that clinical trial evidence suggests ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

复旦大学附属华东医院血液科近日在血液领域权威期刊Blood Cancer Journal上在线发表了题为“Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block”的论文。该研究发现两种药物依托泊苷联合地西他滨治疗极其难治的TP53突变急性髓细 ...

Belgian actress Emilie Dequenne passed away at 43 due to adrenocortical carcinoma (ACC), a rare adrenal gland cancer. ACC is ...

引言小细胞肺癌（SCLC）是肺癌中恶性程度最高的一种类型，其在全部肺癌病例中约占 13%～15%。初治 SCLC 患者虽然对化疗和放疗具有较高的敏感性，但容易复发，导致患者生存率较低。免疫治疗已成为 SCLC 治疗 20 ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...